Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › EWTX

Edgewise Therapeutics

EWTX Lead: Phase 2 3 Biotech Distilled articles ↓ 16 filings & releases ↓ Cash $68.7M (Sep 30, 2026) ↓ 3 verdicts ↓ 4 timing quotes ↓
Cardiovascular Small Molecule

Market cap $4.93B 109.5M shares (10-Q, Oct 31, 2026) × $45.04 close Nov 6, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

9 trackedQuarter catalyst calendar →
  1. mavacamten competitor Ph3 start2026mavacamten competitor Ph3 start, 2026, routine
  2. EDG-7500 FDA feedback2H 2026EDG-7500 FDA feedback, 2H 2026, material
  3. sevasemten topline4Q 2026sevasemten topline, 4Q 2026, material
  4. EDG-7500 Ph3 start4Q 2026EDG-7500 Ph3 start, 4Q 2026, notable
  5. aficamten competitor sNDA filing4Q 2026aficamten competitor sNDA filing, 4Q 2026, notable
  6. EDG-7500 readout1H 2027EDG-7500 readout, 1H 2027, material
  7. BHB-1893 competitor Ph3 start1H 2027BHB-1893 competitor Ph3 start, 1H 2027, routine
  8. EDG-003 corporate update2027EDG-003 corporate update, 2027, routine
  9. aficamten competitor interim2H 2027aficamten competitor interim, 2H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Technology platforms

muscle focused drug discovery platform

Proprietary muscle-focused drug discovery platform using custom high-throughput and translatable systems measuring integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue; focused on rare neuromuscular and cardiac diseases including muscular dystrophies and cardiometabolic diseases.

Targets: sarcomere modulators, myosin

EDG-003

Cardiometabolic discovery program targeting novel cardiometabolic targets; preclinical stage; part of Edgewise's broader muscle-focused drug discovery platform

Discontinued (1)

Capital (as filed)

Cash
$68.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$78.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.64B cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Edgewise Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-09-30 Watch Edgewise Therapeutics, Inc. (EWTX) — Scientific Deep Dive for EDG-7500, EDG-15400 and Pipeline Products At ~$2.6B enterprise value the market already prices a Phase 3 win built on 53 open-label patients whose nHCM symptom gain sits inside placebo responses of two randomized trials; wait for a placebo-controlled Phase 3 design or a price near $26–28.
  2. 2026-11-05 Watch UPDATE: Edgewise Therapeutics (EWTX) - Sold Before the Coin Landed GRAND CANYON failure wipes out the near-term Becker milestone and the cash floor is lower than estimated, leaving ~$2.47B EV resting almost entirely on 53 open-label patients; SPECULATIVE BUY triggers unchanged.
  3. 2026-11-06 Watch UPDATE: Edgewise Therapeutics (EWTX) - The Placebo Arm Arrives STRATUS-HCM delivers the placebo-controlled design with separate cohorts and objective peak VO2 primary endpoint the author asked for, but trough gradient question remains open, nHCM has no Phase 2 VO2 data, and at ~$2.62B EV the price trigger of $25–27 has not been met.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (16)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)